Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that 5q deletion status confers therapeutic sensitivity to Lenalidomide in patients with Myeloproliferative Neoplasm.
The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
This statement is based on a regulatory approval from the European Medicines Agency:
Revlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.